These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37402606)

  • 1. Health-care practitioner use of prescription drug monitoring programs in clinical practice in Australia: A qualitative study.
    Hoppe D; George Liu C; Khalil H
    Drug Alcohol Rev; 2023 Nov; 42(7):1647-1657. PubMed ID: 37402606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.
    Radomski TR; Bixler FR; Zickmund SL; Roman KM; Thorpe CT; Hale JA; Sileanu FE; Hausmann LRM; Thorpe JM; Suda KJ; Stroupe KT; Gordon AJ; Good CB; Fine MJ; Gellad WF
    J Gen Intern Med; 2018 Aug; 33(8):1253-1259. PubMed ID: 29520747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
    Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
    Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provider perspectives and experiences following the integration of the prescription drug monitoring program into the electronic health record.
    Witry M; Marie BS; Reist J
    Health Informatics J; 2022; 28(3):14604582221113435. PubMed ID: 35829729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline.
    Haines S; Lam A; Savic M; Carter A
    Int J Drug Policy; 2022 Nov; 109():103847. PubMed ID: 36067724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use.
    Richwine C; Everson J
    J Gen Intern Med; 2023 Mar; 38(4):881-888. PubMed ID: 36229762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
    Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
    Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstate data sharing of prescription drug monitoring programs and associated opioid prescriptions among patients with non-cancer chronic pain.
    Lin HC; Wang Z; Simoni-Wastila L; Boyd C; Buu A
    Prev Med; 2019 Jan; 118():59-65. PubMed ID: 30316875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping prescription drug monitoring program data to self-report measures of non-medical prescription opioid use in community pharmacy settings.
    Charron E; Brooks JH; Peterson KT; Akinwolere OG; Winhusen T; Cochran G
    Res Social Adm Pharm; 2023 Aug; 19(8):1171-1177. PubMed ID: 37142474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs?
    Smith RJ; Kilaru AS; Perrone J; Paciotti B; Barg FK; Gadsden SM; Meisel ZF
    Pain Med; 2015 Jun; 16(6):1122-31. PubMed ID: 25688454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usability of the Massachusetts Prescription Drug Monitoring Program in the Emergency Department: A Mixed-methods Study.
    Poon SJ; Greenwood-Ericksen MB; Gish RE; Neri PM; Takhar SS; Weiner SG; Schuur JD; Landman AB
    Acad Emerg Med; 2016 Apr; 23(4):406-14. PubMed ID: 26806310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Nobody Knows How You're Supposed to Interpret it:" End-user Perspectives on Prescription Drug Monitoring Program in Massachusetts.
    Hong M; Seymour S; Stopka TJ; Bandanza L; Crocker E; Morgan A; Beletsky L
    J Addict Med; 2022 May-Jun 01; 16(3):e171-e176. PubMed ID: 34417413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Emergency Department Opioid Prescribing Behaviors After Education About Mandated Use of the Pennsylvania Prescription Drug Monitoring Program.
    Martello J; Cassidy B; Mitchell A
    J Addict Nurs; 2018; 29(3):196-202. PubMed ID: 30180006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
    Brown WC; Whitted K
    J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations in prescription drug monitoring program use by prescriber specialty.
    Sun BC; Lupulescu-Mann N; Charlesworth CJ; Kim H; Hartung DM; Deyo RA; John McConnell K
    J Subst Abuse Treat; 2018 Nov; 94():35-40. PubMed ID: 30243415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact evaluation of a brief online training module on physician use of the Maryland, USA, Prescription Drug Monitoring Program.
    Adenaiye OO; Zirpoli JB; Tan M; Day BF; Bolaji O; Mitchell CS; Cloeren M
    PLoS One; 2022; 17(8):e0272217. PubMed ID: 35944051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.